G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia
Jessica Galloway-Peña,Daniel P. Smith,Pranoti Sahasrabhojane,Nadim J. Ajami,W. Duncan Wadsworth,Naval Daver,Roy F. Chemaly,Lisa Marsh,Shashank S. Ghantoji,Naveen Pemmaraju,Guillermo Garcia-Manero,Katayoun Rezvani,Amin M. Alousi,Jennifer A. Wargo,Elizabeth J. Shpall,P.A. Futreal,Michele Guindani,Joseph F. Petrosino,Dimitrios P. Kontoyiannis,Samuel A. Shelburne +19 more
TL;DR: In this article, the authors presented the largest longitudinal analyses to date of oral and stool microbiomes in patients with acute myelogenous leukemia (AML) and suggest that microbiome measurements could assist with the mitigation of infectious complications of AML therapy.
Journal ArticleDOI
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Jorge E. Cortes,Moshe Talpaz,Susan O'Brien,Stefan Faderl,Guillermo Garcia-Manero,Alessandra Ferrajoli,Srdan Verstovsek,Mary Beth Rios,Jenny Shan,Hagop M. Kantarjian +9 more
TL;DR: The authors investigated the significance of the WHO classification system and compared it with the classification systems used to date in imatinib trials (“standard definition”) to determine its impact in establishing the outcome of patients after therapy withImatinib.
Journal ArticleDOI
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
Guillermo Garcia-Manero,Elizabeth A. Griffiths,David P. Steensma,Gail J. Roboz,Richard A. Wells,James K. McCloskey,Olatoyosi Odenike,Amy E. DeZern,Karen W.L. Yee,Lambert Busque,Casey O'Connell,Laura C. Michaelis,Joseph M. Brandwein,Hagop M. Kantarjian,Aram Oganesian,Mohammad Azab,Michael R. Savona +16 more
TL;DR: Oral cedazuridine/decitabine produced similar systemic decitABine exposure, DNA demethylation, and safety vs decitabines 20 mg/m2 IV in the first 2 cycles, with similar efficacy.
Journal ArticleDOI
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia
Alfonso Quintás-Cardama,Hagop M. Kantarjian,Moshe Talpaz,Susan O'Brien,Guillermo Garcia-Manero,Srdan Verstovsek,Mary Beth Rios,Kimberly Hayes,Armand B. Glassman,B. Nebiyou Bekele,Xian Zhou,Jorge E. Cortes +11 more
TL;DR: Treatment with imatinib mesylate overcomes the adverse prognostic significance of der(9) deletions in patients with CML and in a multivariate analysis, der( 9) deleting had no significant impact on response, survival, or response duration.
Journal ArticleDOI
Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
TL;DR: The myelodysplastic disorders are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML).